Per Fischer, MinervaX CEO
October 11, 2023 03:00 AM EDTUpdated 05:39 AM
Financing

Phar­ma-backed Min­er­vaX rais­es €54M as it aims to move its group B Strep­to­coc­cus vac­cine in­to PhI­II

Katherine Lewin

News Reporter

Near­ly a year af­ter rais­ing its largest fi­nanc­ing so far, the Dan­ish biotech Min­er­vaX is back with an up­sized fi­nanc­ing round of €54 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times